LANGHORNE, Pa., Oct. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, is scheduled to participate in the following October 2024 investor conferences.
Maxim’s Healthcare Virtual Summit
Date: October 15-17, 2024
Presentation Format: Fireside Chat with Naz Rahman, Vice President, Biotechnology Analyst
Day and Time: Tuesday, October 15th at 9:30 a.m. ET
Webcast: https://ir.nexgel.com/news-events/events-presentations
LD Micro Main Event XVII Conference Details:
Date: October 28-30, 2024
Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA
Presentation Day and Time: Wednesday, October 30th at 11:30 a.m. PT
Presentation Location: Track 4
Webcast: https://ir.nexgel.com/news-events/events-presentations
To schedule a one-on-one investor meeting with Mr. Levy, please contact your representatives at Maxim and LD Micro or email KCSA Strategic Communications at This email address is being protected from spambots. You need JavaScript enabled to view it..
About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$4.74 |
Daily Change: | 0.08 1.72 |
Daily Volume: | 24,517 |
Market Cap: | US$32.180M |
November 13, 2024 November 11, 2024 October 10, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB